NIDDK Funding Opportunity

R41/R42 Small Business Technology Transfer Grant (STTR)

Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R41/R42)

The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK. Phase I supports preliminary steps in the process for lead optimization or preclinical development of therapeutics. Phase II supports lead optimization and preclinical development of lead candidates and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go/No Go decision points.

Full AnnouncementPA-14-054
Notice(s) for this Opportunity
Open Date3/5/2014
Letter of Intent Due Date
Not Applicable
Application Due Date
Standard dates apply, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NIDDK Program ContactGuillermo Arreaza-Rubin, M.D.
Opportunity Resources
Small Business Opportunities

Print Page

Click outside of the light box to close the box.